MX2022014270A - Polinucleotidos que comprenden una carga util antigenica. - Google Patents
Polinucleotidos que comprenden una carga util antigenica.Info
- Publication number
- MX2022014270A MX2022014270A MX2022014270A MX2022014270A MX2022014270A MX 2022014270 A MX2022014270 A MX 2022014270A MX 2022014270 A MX2022014270 A MX 2022014270A MX 2022014270 A MX2022014270 A MX 2022014270A MX 2022014270 A MX2022014270 A MX 2022014270A
- Authority
- MX
- Mexico
- Prior art keywords
- payload
- polynucleotides
- leader
- signal
- sequence
- Prior art date
Links
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 abstract 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 abstract 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 abstract 1
- -1 LDLRP Proteins 0.000 abstract 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 abstract 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen y divulgan polinucleótidos, andamiajes y casetes en este documento. En particular, estos polinucleótidos pueden tener una fórmula que comprende Señal/Líder-carga útil-PRM, donde la Señal/Líder codifica una secuencia de señal, una secuencia líder o una secuencia de clasificación, en marco con y río arriba de una carga útil; la carga útil es una región de carga útil antigénica, un agente detectable y un agente terapéutico; y el PRM codifica la totalidad o una porción de al menos una región de molécula receptora parental de una o más isoformas o proteínas seleccionadas del grupo que consiste en proteínas CD1d, CD1e, LDLR, LDLRP y LRP1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024604P | 2020-05-14 | 2020-05-14 | |
| PCT/US2021/031947 WO2021231541A1 (en) | 2020-05-14 | 2021-05-12 | Polynucleotides comprising an antigenic payload |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014270A true MX2022014270A (es) | 2023-02-22 |
Family
ID=78524935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014270A MX2022014270A (es) | 2020-05-14 | 2021-05-12 | Polinucleotidos que comprenden una carga util antigenica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230203122A1 (es) |
| EP (1) | EP4149506A4 (es) |
| JP (1) | JP2023527714A (es) |
| KR (1) | KR20230049061A (es) |
| CN (1) | CN115867311A (es) |
| AU (1) | AU2021270879A1 (es) |
| CA (1) | CA3178487A1 (es) |
| IL (1) | IL298166A (es) |
| MX (1) | MX2022014270A (es) |
| TW (1) | TW202207966A (es) |
| WO (1) | WO2021231541A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9809654B2 (en) * | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| GB0314682D0 (en) * | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| US20070269457A1 (en) * | 2006-05-16 | 2007-11-22 | The Buck Institute For Age Research | Immunotherapeutic compositions and methods |
| EP2112930B1 (en) * | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| EP2406290B1 (en) * | 2009-03-10 | 2017-07-05 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
| SG10201601766UA (en) * | 2011-03-10 | 2016-04-28 | Agency Science Tech & Res | METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY |
| CA2832307A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| KR20180006402A (ko) * | 2015-05-22 | 2018-01-17 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항원 제공 단백질에 관련된 방법 및 조성물 |
| SG11201806392XA (en) * | 2016-01-27 | 2018-08-30 | Advaxis Inc | Personalized delivery vector-based immunotherapy and uses thereof |
-
2021
- 2021-05-12 IL IL298166A patent/IL298166A/en unknown
- 2021-05-12 EP EP21803364.5A patent/EP4149506A4/en active Pending
- 2021-05-12 CA CA3178487A patent/CA3178487A1/en active Pending
- 2021-05-12 CN CN202180046220.6A patent/CN115867311A/zh active Pending
- 2021-05-12 AU AU2021270879A patent/AU2021270879A1/en active Pending
- 2021-05-12 JP JP2022569132A patent/JP2023527714A/ja active Pending
- 2021-05-12 US US17/998,574 patent/US20230203122A1/en active Pending
- 2021-05-12 KR KR1020227043497A patent/KR20230049061A/ko active Search and Examination
- 2021-05-12 WO PCT/US2021/031947 patent/WO2021231541A1/en active Application Filing
- 2021-05-12 MX MX2022014270A patent/MX2022014270A/es unknown
- 2021-05-13 TW TW110117295A patent/TW202207966A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149506A4 (en) | 2024-05-29 |
| TW202207966A (zh) | 2022-03-01 |
| CA3178487A1 (en) | 2021-11-18 |
| WO2021231541A1 (en) | 2021-11-18 |
| KR20230049061A (ko) | 2023-04-12 |
| US20230203122A1 (en) | 2023-06-29 |
| AU2021270879A1 (en) | 2022-12-15 |
| IL298166A (en) | 2023-01-01 |
| JP2023527714A (ja) | 2023-06-30 |
| CN115867311A (zh) | 2023-03-28 |
| EP4149506A1 (en) | 2023-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gorfu et al. | Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii | |
| Mladinich et al. | Zika virus persistently infects and is basolaterally released from primary human brain microvascular endothelial cells | |
| Moore et al. | The entry of entry inhibitors: a fusion of science and medicine | |
| Sainz Jr et al. | ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells | |
| Zea et al. | Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy | |
| Kottke et al. | Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors | |
| Wollner et al. | A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses | |
| Zeng et al. | Neutralization of SARS-CoV-2 variants of concern harboring Q677H | |
| Ketas et al. | Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells | |
| Pinto et al. | Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection | |
| Tavares et al. | Roles of cell adhesion and cytoskeleton activity in Entamoeba histolytica pathogenesis: a delicate balance | |
| DK0996717T3 (da) | Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination | |
| DK0493427T3 (da) | System til at fuldføre et opkald | |
| UA119226C2 (uk) | Антитіло, яке специфічно зв'язується з axl, та його застосування як продукту для адресної доставки при лікуванні раку | |
| DK0851927T3 (da) | Forbindelser til immunterapi og diagnosticering af tuberkulose | |
| Gerhard et al. | Cellular uptake of Clostridium difficile TcdA and truncated TcdA lacking the receptor binding domain | |
| Long et al. | γδ T cells play a protective role in chikungunya virus-induced disease | |
| CY1107448T1 (el) | Συνθεσεις και εμβολια που περιεχουν αντιγονο(-α) cryptosporidium parvum και αλλου εντερικου παθογονου | |
| Nagai et al. | Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18 | |
| Wang et al. | Expression of interleukin‐18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells | |
| Yermakova et al. | Antibody-mediated inhibition of ricin toxin retrograde transport | |
| MX2022014270A (es) | Polinucleotidos que comprenden una carga util antigenica. | |
| Ozaki et al. | Porphyromonas gingivalis fimbriae inhibit caspase-3-mediated apoptosis of monocytic THP-1 cells under growth factor deprivation via extracellular signal-regulated kinase-dependent expression of p21 Cip/WAF1 | |
| EP2502998A3 (en) | Recombinant toxin A/ToxinB vaccine against clostridium difficile | |
| DE69732709D1 (de) | Expressionsblockierung von virulenten faktoren in s. aureus |